Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell Q4 revenues fall
Operating loss for the fourth quarter of 2010 was EUR198.94m, compared to EUR7.93m for the same period in 2009. Intercell has generated gross profit was EUR7.63m, compared to
Operating loss for the fourth quarter of 2010 was EUR198.94m, compared to EUR7.93m for the same period in 2009. Intercell has generated gross profit was EUR7.63m, compared to
As per the terms of the transaction, each outstanding share of King Pharma common stock has been converted into the right to receive $14.25, net in cash (without
Valeritas has examined Humalog and NovoLog and found safe for use with the V-Go Disposable Insulin Delivery Device. The V-Go is small, lightweight, and worn under the patients’
The Regulatory Affairs and Quality Assurance consultancy, Regulus is expected to work as the Regulatory Affairs, Strategic Development, and Quality Assurance consultancy division of Clinipace Worldwide. With is
ThermoDox is currently being assessed under a Special Protocol Assessment with the US Food and Drug Administration in a 600 patient pivotal Phase III trial, the HEAT study,
MetaVision was chosen to standardize and improve data collection, to track performance measures, and to report on anesthesia quality and compliance indicators. The MetaVision Anesthesia Information Management System
SuperGen has posted a net income of $6.75m for the fourth quarter of 2010, compared to $2.34m for the same period in 2009.SuperGen’ income from operations was $6.49m,
In this collaboration, tumor specimens from subjects treated with IRX-2 and control subjects will be analyzed by the collaborating company using gene analysis technology in order to characterize
Previously those products were marketed by ‘Kyowa Kyowa Hakko Bio, reported thehindubusinessline.com. Daiichi Sankyo and Kyowa Hakko Bio had agreed to transfer the marketing rights of the products
Earlier in February 2010, Meda has got exclusive license for marketing, selling and distributing Xerese in the US, Canada and Mexico for the treatment of cold sores (herpes